- Previous Close
0.0000 - Open
0.0001 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0001 - 52 Week Range
0.0001 - 4.2500 - Volume
100 - Avg. Volume
3,999 - Market Cap (intraday)
1,898 - Beta (5Y Monthly) 1.59
- PE Ratio (TTM)
-- - EPS (TTM)
-15.6400 - Earnings Date Sep 27, 2024 - Oct 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
www.evelobio.com66
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: EVLO
View MoreCompare To: EVLO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EVLO
View MoreValuation Measures
Market Cap
1.90k
Enterprise Value
16.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-83.25%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-82.35M
Diluted EPS (ttm)
-15.6400
Balance Sheet and Cash Flow
Total Cash (mrq)
17.26M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-43.31M